Roswell Park at ASH

Saturday, December 7th, 2024

• Dr. Matthew Cortese presenting 78 - Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment
• Dr. Lisa Niswander presenting 370 - Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias

Sunday, December 8th, 2024 

• Dr. Matthew Cortese presenting 525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
• Dr. Kara Kelly presenting 462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
• Janine Joseph, MS, MBA, presenting 705 - Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Monday, December 9th, 2024 

• Taylor Mandeville, BA, presenting 1036 - Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Sunday, December 8th, 2024

• Dr. Matthew Cortese is senior author on 3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
• Dr. Ehsan Malek presenting 3445 - Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)
• Dr. Showkat Hamid presenting 3432 - Correlation of Serum Inflammatory State and Macrophage Phenotype with CAR T Cell Expansion and Clinical Outcomes Dr. Marco Davila is senior author.

Monday, December 9th, 2024

• Dr. Muhammad Tariq presenting 4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
• Dr. Jens Hillengass is senior author on 4678 - Differences in Immune Cell Populations between Individuals with or without MGUS
• Dr. Esraa Abdalla and Dr. Catherine Forbes presenting 5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center
• Dr. Sawyer Bawek presenting 4236 - Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy Dr. Eunice Wang is senior author.

• 6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study - Dr. Eunice Wang
• 3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL - Dr. Francisco Hernandez-Ilizaliturri
• 861 - Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaMâ„¢) - Dr. Francisco Hernandez-Ilizaliturri
• 111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study - Dr. Francisco Hernandez-Ilizaliturri & Dr. Alex Niu
• 72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study - Dr. Francisco Hernandez-Ilizaliturri